Investing.com
Reverse Mergers Now Rival Biotech IPOs in 2026, and the Aethlon Deal Shows Why
What a biotech deal reveals about the listing market, and why the reported financing figure needed a second look.
Read article: Reverse Mergers Now Rival Biotech IPOs in 2026, and the Aethlon Deal Shows Why on Investing.com (opens in a new tab)